GYL Financial Synergies LLC raised its position in GlaxoSmithKline plc (NYSE:GSK) by 14.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,562 shares of the pharmaceutical company’s stock after buying an additional 684 shares during the period. GYL Financial Synergies LLC’s holdings in GlaxoSmithKline were worth $261,000 at the end of the most recent quarter.
Other institutional investors have also made changes to their positions in the company. Boston Partners increased its stake in shares of GlaxoSmithKline by 475.2% in the fourth quarter. Boston Partners now owns 8,184,315 shares of the pharmaceutical company’s stock valued at $384,575,000 after purchasing an additional 6,761,520 shares during the period. Fisher Asset Management LLC increased its stake in GlaxoSmithKline by 10.2% in the 3rd quarter. Fisher Asset Management LLC now owns 15,267,588 shares of the pharmaceutical company’s stock worth $651,621,000 after purchasing an additional 1,412,368 shares in the last quarter. Beutel Goodman & Co Ltd. acquired a new stake in GlaxoSmithKline during the 3rd quarter worth about $14,000,000. Douglas Lane & Associates LLC acquired a new stake in shares of GlaxoSmithKline during the third quarter valued at approximately $17,372,000. Finally, Voloridge Investment Management LLC boosted its position in shares of GlaxoSmithKline by 126.2% in the third quarter. Voloridge Investment Management LLC now owns 531,393 shares of the pharmaceutical company’s stock worth $22,680,000 after buying an additional 296,496 shares during the period. Institutional investors own 11.27% of the company’s stock.
Shares of GSK stock opened at $43.58 on Thursday. GlaxoSmithKline plc has a 12 month low of $38.43 and a 12 month high of $48.25. The company has a quick ratio of 0.56, a current ratio of 0.81 and a debt-to-equity ratio of 1.29. The business’s 50 day moving average is $46.66 and its two-hundred day moving average is $43.89. The company has a market cap of $111.27 billion, a PE ratio of 18.31, a price-to-earnings-growth ratio of 4.48 and a beta of 0.71.
The company also recently declared a quarterly dividend, which will be paid on Thursday, April 9th. Stockholders of record on Friday, February 21st will be given a $0.5994 dividend. This is a positive change from GlaxoSmithKline’s previous quarterly dividend of $0.50. The ex-dividend date is Thursday, February 20th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 5.50%. GlaxoSmithKline’s dividend payout ratio (DPR) is currently 62.15%.
GSK has been the subject of several recent research reports. ValuEngine upgraded GlaxoSmithKline from a “sell” rating to a “hold” rating in a report on Thursday, February 6th. Svb Leerink initiated coverage on shares of GlaxoSmithKline in a research note on Monday, December 2nd. They issued an “outperform” rating for the company. Leerink Swann assumed coverage on shares of GlaxoSmithKline in a research report on Monday, December 2nd. They issued an “outperform” rating and a $53.00 target price for the company. Shore Capital lowered shares of GlaxoSmithKline from a “hold” rating to a “sell” rating in a research note on Wednesday. Finally, Barclays lowered GlaxoSmithKline from an “equal weight” rating to an “underweight” rating in a report on Thursday, January 16th. Three analysts have rated the stock with a sell rating, five have given a hold rating and six have given a buy rating to the company’s stock. GlaxoSmithKline has an average rating of “Hold” and a consensus price target of $47.33.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Further Reading: Growth Stocks
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.